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Abstract 
This study explored the mediating factors of sarcopenia in a group of women 
survivors of breast cancer in Bogotá, Colombia. This was a descriptive cross-
sectional study with 98 women survivors of breast cancer, who were registered with 
the SIMMON (Integrated Synergies to Improve Oncological Management in 
Colombia) Foundation. Body weight, height, and waist circumference (WC) were 
measured, and body mass index (BMI) was calculated. Body composition 
(percentage of fat and muscle mass) was evaluated via four-pole bioelectrical 
impedance analysis. Sarcopenia was defined as low muscle mass plus low grip 
strength or low gait speed (EWGSOP criteria). A "causal" mediation analysis with 
the Baron & Kenny procedure (PROCESS® macro) was used to explore variables 
related to sarcopenia. Analyses were performed with the IBM SPSS 21 statistical 
package (SPSS, Inc., Chicago, Illinois, USA). The significance level of the results 
obtained in the hypothesis contrast was p < 0.05. The mean age of the sample was 
65.5±5.9 years, with a BMI of 27.8±4.7 kg/m2. The prevalence of sarcopenia was 
22.4%. Linear regression models suggest a partial mediation of anthropometric 
parameters (body mass, body mass index and waist circumference) in the 
association between handgrip strength and muscle mass. In conclusion, one in every 
five women survivors of breast cancer had sarcopenia. The findings seem to 
emphasize the importance of obesity prevention in women survivors of breast 
cancer, suggesting that high handgrip strength may not relate closely to greater 
muscle mass and therefore would not exclude the risk of sarcopenia. 
Keywords: prevalence; body composition; sarcopenia; breast cancer; physical 
performance; adults 
  
1. Introduction 
Cancer is one of the main causes of death on a global scale. In 2012, 8.2 million 
registered deaths were attributed to this cause [ 1 ]. In Colombia, according to 
statistics presented by the 2012 GLOBOCAN project (International Agency for 
Research on Cancer) of the World Health Organization (WHO), approximately 104 
people died each day due to this disease and 196 people contracted cancer each day 
[2 ]. An analysis from the Sub-direction for Non-communicable Diseases at the 
Ministry of Health and Social Protection shows that breast cancer in Colombia is 
classified as a public health problem. It is estimated that nearly 8,600 cases are 
detected per year, and the highest numbers of new cases are registered in the cities 
of Bogotá, Medellín, Cali, Barranquilla, Cartagena, Bucaramanga, Santa Marta, and 
San Andrés [3]. Likewise, the World Health Organization reports that breast cancer 
is the most frequent type of cancer among women, representing 16% of all cancers 
in women. In Colombia, breast cancer shows a higher mortality rate than any other 
clinical entity (approximately 2,649 deaths/year for every 100,000 inhabitants) [3]. 
Recent scientific progress in cancer screening, diagnosis, and treatment 
translates into a greater prevalence of cancer and an increased number of survivors 
[1.2]. In addition, the treatments that women undergo after being diagnosed with 
breast cancer produce adverse changes, principally in their quality of life and 
functional capacity [4]. One factor that seems to potentially produce a significant 
reduction in morbidity and mortality in survivors of any type of cancer is 
maintenance of adequate body weight, especially in relation to body composition 
(muscle tissue and fat distribution) [5]. Regarding body composition, people who 
endure neoplastic diseases show lower lean body mass, with conserved or increased 
percentages of fat [6]. Thus, the relationship that is frequently observed between 
reduced muscle mass and strength is often independent of the proportion and 
distribution of adipose tissue [7,8]. 
 In addition, sarcopenia– a condition characterized by loss of skeletal muscle mass and 
function – is also related to mobility disorders, a higher risk of falls and fractures, 
deterioration of the capacity to perform everyday activities, disability, loss of 
independence, and a greater risk of death [9]. It has been reported that another 
frequent and persistent problem for many breast cancer survivors is increased 
weight. In obese cancer patients who lose muscle mass, this culminates in sarcopenic 
obesity (SO), a condition that may be masked by the excess fat mass [10]. SO was 
defined for the first time in 1996 as the combination of reduced fat-free mass and 
excess fat mass, evaluated by bioimpedance analysis (BIA) and expressed as body 
weight percentage [6]. Low muscle density, low muscle strength and a higher 
proportion of fat infiltration within muscle have recently been recognized as 
additional features of sarcopenia along with muscle depletion [10,11].  
Additionally, observational studies show that the side effects of cancer 
treatment can include a metabolic state that induces muscular dysfunction, 
sarcopenia, and SO [ 12 , 13 ]. In breast cancer survivors, some non-conclusive 
evidence seems to exist that mortality for overweight and obese women is worse 
than for women with normal weight, even with the same diagnosis. One possible 
reason for this association is that comorbidity might be more common in sarcopenic 
patients as a result of potentially decreased overall health status [ 14 ]. Another 
explanation may be due to the pharmacokinetics of cytotoxic drugs; individual 
variations in cancer patients may cause the drug distribution volume to vary up to 
threefold in relation to the corresponding body surface area, on which the dosage 
conventionally is determined [10]. Thus, SO patients may have a higher 
susceptibility to toxicity compared to obese patients with a normal lean body mass 
[10]. Although the exact mediating factors in relation to sarcopenia and SO are not 
fully understood, these body composition types have been associated with cancer 
complications. 
Although sarcopenia is a problem affecting public health and the quality of life 
of patients who have completed breast cancer treatment, few studies in Colombia 
have addressed its prevalence or the factors that can be related to this clinical 
manifestation. The present study focuses on determining the mediating factors of 
sarcopenia in a group of women who survived breast cancer in Bogotá (Colombia). 
2. Methods 
2.1. Study Desing and Sample Population 
During 2015 and 2016, a cross-sectional study was conducted on 98 women over 
60 years of age who lived in the city of Bogotá and were registered with the 
SIMMON Foundation. The study recruited women "cancer survivors" – defined in 
2011 by the Centers for Disease Control and Prevention as those individuals who 
have been diagnosed with cancer, from the moment of the diagnosis to the rest of 
their lives – ranging in age from 60 to 75 years and residing in the urban zone of the 
city of Bogotá (Colombia). The study excluded women with acute conditions or 
chronic acutely decompensated conditions, pacemaker-type devices, terminal 
chronic kidney disease being treated by hemodialysis, or musculoskeletal diseases 
that limit implementation of tests.  
2.2. Data Collection 
Participants who accepted and signed the informed consent provided 
information about their clinical history, indicating personal and family disease 
antecedents, sociodemographic aspects, education and socioeconomic level, and 
other information. The anthropometric evaluation included measurements of height 
registered in a stretched position with portable stadiometer (Seca 206®; Hamburg, 
Germany) (range 0 – 220 cm) with 1 mm precision. Weight was measured with a 
Tanita floor scale (Seca mBCA 515®, HANS E. RÜTH S.A., Hamburg, Germany) 
with a maximum capacity of 200 kg and minimum capacity of 100 g. These variables 
were used to calculate the BMI in kg/m2, adopting the cut-off recommended by the 
World Health Organization. Thereafter, waist circumference (WC) was measured 
with using a plastic measuring tape with 1-mm precision (Holtain Ltd., Crymych 
Dyfed, RU), using the anatomic reference points described by the World Health 
Organization. Evaluation of body composition (fat mass and muscle mass) was 
conducted via tetrapolar bioelectrical impedance analysis (BIA) (Seca mBCA 515®, 
HANS E. RÜTH S.A., Hamburg, Germany) by following the indications and 
equations indicated in the user manual. Induction frequency was evaluated at an 
intensity of 50 kHz, with 0.1 kg (0.1%) fat mass estimation sensitivity. This analyzer 
allowed us to ascertain fat mass (% and kg), muscle mass (% and kg), 
musculoskeletal mass (kg), and skeletal muscle mass index (kg/m2). No patients had 
clinically detectable edema, a condition that could have affected resistance and 
reactance. This measurement was carried out with an empty bladder and on a non-
conducting stable surface, following 10-12 h of fasting. 
For sarcopenia diagnosis, the study followed the guidelines furnished by the 
European consensus for its definition and diagnosis (European Working Group on 
Sarcopenia in Older People, EWGSOP) [ 15 ]. These guidelines included the 
confirmation of criteria to classify the population according to the stage of 
sarcopenia, with the first criterion referring to low muscle mass, the second criterion 
related to low muscle strength, and the third criterion based on low physical 
performance. To be diagnosed with sarcopenia, a woman needed to fulfill criterion 
number 1 in addition to criterion 2 or 3 (Table 1). 
Table 1. Diagnostic criteria of sarcopenia according to EWGSOP 
Stage  Muscle mass Muscle strength  Physical performance 
Pre-sarcopenia +    
Sarcopenia + + and/or + 
Severe sarcopenia + +   + 
 
The skeletal muscle mass index (criterion of muscle mass) was determined 
through tetrapolar BIA (Seca mBCA 515®, HANS E. RÜTH S.A., Hamburg, 
Germany) [15]. For muscle strength, handgrip strength was measured with a digital 
dynamometer (0.1 kg precision by Takei Smedley III T-19®, Scientific Instruments 
Co. Ltd, Japan) by conducting two alternate attempts with each hand in a 
standardized standing position, with the arms parallel to the body but not touching 
it. While measurements were being conducted, participants were not to lift their 
hands or move from their original position. In addition, the women were urged 
verbally, in a standardized manner, to apply their maximum strength. 
Dynamometry was performed in duplicate on both hands with approximately 1 min 
of rest between measurements, and the highest value of the four measurements was 
used as an indicator of muscle strength in kg. For physical performance, the study 
applied the Short Physical Performance Battery by following the protocol from the 
validation for Colombia [16]. This study evaluated chair stand and sitting tests 
(registering the number of repetitions), equilibrium (time in s) and gait speed (m/s). 
To establish “severe sarcopenia”, women were required to present low muscle 
mass <6.42 kg/m2 in the skeletal muscle mass index, low muscle strength <20 kg in 
the handgrip strength test, and ≤ 0.8 m/s in the gait speed test, as indicator of low 
physical performance [15]. For the stage of “sarcopenia”, women had to have low 
muscle mass, along with low muscle strength or deficient physical performance. 
Lastly, women with low muscle mass, but without changes in muscle strength or 
physical performance were classified in the “pre-sarcopenia” stage. Women who 
only had low values of muscle strength through handgrip test, but adequate values 
of muscle mass and physical performance were classified at “risk of sarcopenia”. 
Finally, to define SO, we applied the equation by Kim et al., [17] which required the 
participant to have a muscle mass percentage <30.7% of the total weight and fat mass 
percentage >31.7%, determined through tetrapolar BIA (Seca mBCA 515®, HANS E. 
RÜTH S.A, Hamburg, Germany). 
2.3. Ethics Statement 
The study was conducted in accordance with the Helsinki Declaration for 
Human Studies and approved by the Colombian Data Protection Authority 
(Resolution 008430/1993 Ministry of Health) and the Review Committee for 
Research on Human Subjects at the University of Rosario (Code CEI-ABN026-
000173). All participants were informed of the study’s goals, and written informed 
consent was obtained. 
2.4. Statistical Analysis 
Information was processed and analyzed with the Statistical Package for Social 
Science® software, version 21 (SPSS; Chicago, IL, USA). The normality of the 
distribution of the variables was tested using the Kolmogorov-Smirnov test. 
Characteristics of body composition and physical condition of the study were 
presented with mean values, standard deviation (SD), and frequencies. Prevalence, 
expressed in proportions, was calculated according to the number of patients who 
had one or more criteria for diagnosis of sarcopenia or SO. Differences between the 
categories of sarcopenia and the variables studied were analyzed through analysis 
of variance (ANOVA) in the continuous variables and the linear chi squared test on 
variables of proportion. To examine whether the association between handgrip 
strength and muscle mass was mediated by anthropometric parameters, linear 
regression models were fitted using bootstrapped mediation procedures included in 
the PROCESS SPSS macro [ 18 ]. The test of multicollinearity was done before 
analyzing mediation models due to relationship between dependent and mediators 
variables. The tolerance value and variance inflation factors value appeared normal 
with values ranging between 0.119 and 0.446 [19] for collinearity tolerance and 2.244 
and 8.396 for collinearity [20]. The results were statistically significant with p <0.05.  
3. Results 
3.1. Descriptive Characteristics 
Sociodemographic variables, body composition, and diagnostic criteria for 
sarcopenia are shown in Table 2. In the entire sample, the mean age was 65.53±5.91 
years, weight was 63.95±11.3 (kg), BMI was 27.88±4.71 kg/m2, skeletal muscle mass 
index was 7.31±1.07 kg/m2, handgrip strength was 16.79±4.98 kg, and physical 
performance evaluated through gait speed was 1.22±0.40 m/sec. The prevalence 
rates of sarcopenia and SO was were 22.4% and 16.3%, respectively.  
 
 
Table 2. Clinical characteristics of the population women survivors of breast cancer, Bogotá-Colombia 
Characteristics n = 98 
Age (Years) 65.53±5.91 
Level of schooling*  
Primary 48 (48.9) 
High school 43 (43.8) 
Professional 7 (7.1) 
Socioeconomic level*  
1 9 (9.2) 
2 37 (37.8) 
3 39 (39.8) 
>4  13 (13.2) 
Body composition and anthropometry   
Weight (kg) 63.95±11.3 
Height (cm) 1.51±0.06 
Waist (cm) 90.87±12.94 
BMI (weight/height²) 27.88±4.71 
Nutritional classification*  
Normal weight 26 (26.5) 
Overweight 38 (38.8) 
Obesity  34 (43.7) 
Lean mass (kg) 36.34±5.77 
Skeletal muscle mass (kg) 16.79±2.88 
Fat mass (kg) 27.27±7.85 
Fat mass (%) 41.51±6.14 
Skeletal muscle mass index (absolute muscle mass/size2)  7.31±1.07 
EWGSOP indicators  
Muscle strength (kg)  16.79±4.98 
Gait speed (m/sec) 1.22±0.40 
Chair stand (Rep.) 15.6±5.83 
Equilibrium (sec) 9.15±3.08 
Sarcopenia  22 (22.4) 
Sarcopenic obesity* 16 (16.3) 
Data are shown as mean and ± standard deviation. *These variables are expressed in absolute frequencies and 
percentages. 
3.2. Body composition and sarcopenia stages from the EWGSOP 
Table 3 presents the sample distribution according to the stages proposed in this 
work (healthy, risk of sarcopenia, presarcopenia, sarcopenia, severe sarcopenia) and 
the variables studied. In the absence of sarcopenia (healthy/risk of sarcopenia), 
significantly lower values were observed in the anthropometric variables (weight, 
WC, and fat mass).
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Table 3. Distribution of body composition variables according to the sarcopenia stages from the EWGSOP 
*p<0.05 expresses significant differences with the reference group (normal) through one-way ANOVA test, and the multiple comparisons with Bonferroni test.
n=98 Healthy n=22 Risk of Sarcopenia n=41 Presarcopenia n=6 Sarcopenia n=22 Severe sarcopenia n=7 P for trend 
Age (Years) 64.27±5.45 65.96±5.94 64.17±5.19 67.27±6.43 66.29±6.10 0.502 
Body composition and anthropometry       
Weight (kg) 70.37±14.31 66.41±8.5 59.35±8.46* 56.21±14.21* 56.51±6.20* 0.000 
Height (m) 1.52±0.04 1.49±0.04 1.56±0.05 1.53±0.06 1.48±0.06 0.024 
Waist (cm) 96.05±12.14 93.22±10.01 81.67±10.72* 84.08±10.75* 89.94±25.45 0.005 
BMI (height/size²) 30.10±5.63 29.59±3.72 24.30±3.06* 24.19±2.81* 25.46±2.90* 0.000 
Normal weight, (%) 4 (18.2) 2 (4.9) 3 (50.0) 14 (63.6) 3 (42.9) 
0.149 Overweight n, (%) 7 (31.8) 20 (48.8) 3 (50.0) 6 (27.3) 1 (14.3) 
Obesity n, (%) 11 (50.0) 19 (46.3) 0 (0.0) 2 (9.1) 3 (42.9) 
Lean mass (kg) 36.45±10.59 37.62±3.95 33.71±10.35 32.84±4.28 32.21±2.82 0.052 
Skeletal muscle mass (kg) 18.29±3.43 17.59±2.68 16.19±1.89 14.79±1.56* 13.88±1.64* 0.000 
Fat mass (kg) 30.30±9.37 28.34±7.29 23.20±3.88* 22.27±6.17 24.29±4.55 0.002 
Fat mass (%) 42.94±5.60 42.13±11.48 37.80±2.86 38.63±5.73 42.71±4.23 0.100 
Skeletal muscle mass index (absolute 
muscle mass/size2) 
7.86±1.39 7.79±2.07 6.58±0.73* 6.27±0.32* 6.33±0.49* 0.000 
EWGSOP indicators       
Muscle strength (kg)  23.43±2.67 15.18±3.43* 21.12±1.79 13.99±3.91* 13.21±5.16* 0.000 
Gait speed (m/sec) 1.19±0.35 1.29±1.64 1.37±0.24 1.24±0.33 0.79±0.07* 0.027 
Chair stand (rep) 16.0±3.67 16.4±5.79 15.8±2.29 13.5±2.53* 13.4±2.72* 0.000 
Equilibrium (sec) 9.40±1.5 9.20±2.0 9.15±1.18 9.13±1.35 9.08±1.14 0.462 
Sarcopenic obesity n, (%) 0 (0.0) 4 (18.2) 1 (16.7) 9 (40.9)* 2 (28.5) 0.023 
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3.3. Body composition and mediation analysis 
We performed a mediation analysis to test whether anthropometric parameters acted as 
mediator variables between muscle mass (dependent variable) and handgrip strength 
(independent variable) (Figure 1). In the first regression (equation 1), handgrip strength 
was negatively associated with the anthropometric parameters (body mass, BMI and WC) 
(P < 0.01). In the second regression (equation 2), handgrip strength was positively 
associated (P = 0.002) with the dependent variable (muscle mass). In the last regression 
model, the mediator variable was negatively associated with the dependent variable 
(equation 3) (P < 0.01), but when anthropometric parameters (body mass, BMI and WC) 
were included in the model (equation 3’), the regression coefficient did not maintain its 
statistical significance (full mediation) with body mass (P = 0.065) but did so with BMI and 
WC (partial mediation). 
Figure 1. Unstandardized regression coefficients examining the association of pubertal stage and cardiometabolic 
risk score adjusted by age. 
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4. Discussion 
As far as we know, our study is the first to evaluate the mediating role of anthropometric 
parameters (i.e. body mass, BMI and WC) in the relationship between handgrip strength and 
muscle mass, the pivotal parameter in the definition of sarcopenia [15,21]. In our sample, 
approximately one in every five women who had survived breast cancer had sarcopenia. 
Mediation analysis seems to emphasize the importance of obesity prevention in women 
survivors of breast cancer, suggesting that high levels of handgrip strength may not be closely 
related to greater muscle mass. In this line, the potential role of behavioral interventions, 
nutritional changes, and pharmacological strategies to attenuate obesity-related inflammation 
is a key research objective. 
Using the criteria defined by the EWGSOP, this study detects a 22.4% prevalence of 
sarcopenia, a higher prevalence than was found in studies published by Baumgartner et al. [22] 
(13%), Melton et al. [23] (8%), Villasenor et al. [14] (15%), and Yamada et al. [24] (11.5%). Other 
published studies, which use bioelectrical impedance to measure muscle mass and apply the 
EWGSOP criteria for sarcopenia diagnosis, also yield results quite different from those found 
in this work. For example, a reanalysis of the study by InCHIANTI [25] in a population of 538 
elderly Italian adults, using the muscle mass cut-off recommended in the EWGSOP consensus, 
found that the prevalence of sarcopenia in the age range of 70 to 74 years was 1.2% in men and 
2.6% in women.  
Several studies have examined the prevalence of sarcopenia in Latin American 
populations. In a sample of Mexican adults with a mean age of 78.5±7 years, Arango et al. [26] 
reported a 33.6% prevalence of sarcopenia according to the EWGSOP criteria. Although these 
authors did not discriminate prevalence by age range or classification on the sarcopenia 
spectrum, the high frequency may be due to the choice of skeletal muscle mass indicator (calf 
circumference), which limits the possibility of comparison with the current study. In 91 elderly 
Brazilians with a mean age of 61.9±8.7 years, Castro et al., [27] reported a 12% prevalence of 
sarcopenia according to the criteria defined by Chien et al. [28]. In Colombia, a study by 
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González-González et al. [ 29 ], using the EWGSOP criteria from 2009, describes a 13.8% 
prevalence of sarcopenia in 81 women with a mean age of 69.6±3.1 years from the city of 
Manizales.  
The large observed variations in prevalence among studies are because consensus has yet 
to be reached on the criterion of muscle mass below which sarcopenia should be diagnosed. 
Another possible explanation may be the nutritional deterioration to which cancer patients are 
exposed, mostly based on the involuntary loss of weight, a frequent condition accompanied by 
reduced intake and systemic inflammation [30]. Within this context, it has been reported that 
process of muscle mass loss is due to protein degradation mediated by the activation of the 
ubiquitin-dependent proteasome pathway [31] and, hence, on loss of muscular function [32].  
Along with a decrease in muscle size, one of the major contributing factors to the loss of 
strength and functional capacity is also related with a decrease in muscle quality as a 
consequence of increased amount of intramyocellular adipose tissue (i.e., muscle fat 
infiltration) and conective tissue [33,34,35], together with a loss of spinal MNs that leads to a 
decline in in the size and/or number of individual muscle fibers, especially of fast-twitch fibers 
(i.e. sarcopenia) [36]. Also highlighted is the increase in inflammatory cytokines secreted by the 
immune system and adipose tissue, such as tumor necrosis factor (TNF)-α or interleukin (IL)-
1, or by the tumor itself, i.e., specific catabolic factors of PIF-type tumors [37], which activate 
enzymes that induce protein replacement in skeletal muscle. In a parallel manner, synthesis 
signals are inhibited, including those produced through anabolic hormones such as insulin-like 
growth factor 1 and testosterone [38]. Another aspect to consider is the decrease in muscle mass 
that occurs during the aging process and during cancer; both of which are strongly tied to 
increased fat mass. Along these lines, Cesari et al. [39] reported that IL-6 and TNF-α were 
related positively to fat mass and negatively to muscle mass, participating actively in the 
development of sarcopenia [40,41] by provoking an involuntary loss of muscle mass without 
initial weight loss. Similarly, high concentrations of IL-6 and TNF-α have been reported in the 
metabolic states of sarcopenia [42], obesity [43], and SO [44]. 
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With respect to the components of sarcopenia, low values of handgrip strength and skeletal 
muscle mass index were the most prevalent components, with prevalence rates of 77.6% and 
37.8%, respectively, while lower physical performance in the gait speed test had a lower 
frequency (18.4%). These modifications significantly alter the protein deposits as much as 
muscle functionality; accordingly, several works report that sarcopenia is the primary cause of 
fragility in elderly adults [45]. 
This work showed that 16.3% of the women evaluated had SO, with the highest frequency 
(40.9%) occurring in the group of women with sarcopenia. From a clinical perspective, changes 
in body composition taking place in cancer patients indicate the possible combination of low 
muscle mass and high fat mass, which triggers SO due to the co-existence of excess adiposity 
and sarcopenia [45]. In this regard, different studies [46,47] show that up to 60% of patients 
with breast cancer gain weight, and this increase is associated with adverse results, such as 
diseases associated with obesity. In addition, deregulation of adipocytokines secreted by 
adipose tissue and by cells under oxidative stress act in synergy on the metabolic anomalies 
related to obesity [45]. Positive energy balance due to reduced energy expenditure at rest and 
reduced exercise during treatment could also cause an increase in fat mass, particularly of 
central fat mass, and thereby produce weight gain [48]. 
In many cases of SO, a state of insulin resistance facilitates the onset of cardiovascular 
diseases, such as ischemic heart disease, cerebrovascular disease, and essential arterial 
hypertension, whose etiology is related to insulin resistance syndrome [49]. In this sense, SO, 
represented by increased adiposity, has been associated with a defect in the insulin signaling 
pathway at a post-receptor level and impaired glucose transport through the insulin-regulated 
glucose 4 transporter pathway [50]. 
Although several studies have examined the relationship between evaluation components 
for sarcopenia diagnosis, the mediating role of body composition variables, for example, the 
relationship between muscle strength and muscle mass, is still unknown [50,51]. Likewise, our 
results reveal partial mediation with indicators of adiposity (BMI and WC), while total 
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mediation was observed with the body mass (kg) variable. In this aspect, it has been confirmed 
that changes in muscle composition and architecture (e.g., infiltration of intramuscular fat) are 
related to lower physical performance and function [52]. It is also known that increased adipose 
tissue, especially in abdominal obesity, induces metabolic disorders, such as insulin resistance, 
through diverse pathways that imply the involvement of adipocytokines [50,52]. Patients with 
SO have shown that loss of muscle mass is counterbalanced with increased adipose tissue, an 
aspect that is not evident when only body weight is measured. Thus, our results reveal the 
influence of the anthropometric component on muscle mass. Hence, maintaining values >20 kg 
in muscle strength as measured through dynamometry, along with fat mass values <31.7% and 
healthy body weight, seems to be a measure that would benefit the muscles as endocrine organs 
[50-52]. 
Studies in a population of cancer survivors have demonstrated that the parameters of body 
composition are affected after adjuvant therapies are administered as part of treatment [6-8,10]. 
Other studies evidence that improved muscle mass and diminished adiposity can prevent 
weight gain and adverse changes in body composition [8,9,50]. Thus, our findings suggest that 
intervention programs in women who have survived breast cancer must concentrate on the 
component of muscle strength and control the co-variables of body composition, thereby 
improving the quality of the skeletal muscle. Longitudinal studies and controlled clinical trials 
must be performed to investigate in depth the effects of physical exercise on the criteria of 
physical performance, strength, muscle mass, and inflammatory and cardiometabolic markers 
[48,53]. An integrated approach will include timely dietary counselling and physical activity. 
There is evidence to show that complying with a supervised exercise program may help 
mitigate muscle wasting [54] and sarcopenia [55]. 
Some aspects must be kept in mind as limitations in this study. For example, the sample 
size, characteristics of the population, study design, and type of sampling can be considered 
potential sources of bias. Other variables that can be associated with obesity/sarcopenia were 
not included, such as ethnicity, nutritional aspects, and levels of physical activity. Another 
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limitation to our study was the use of BIA to assess body composition. EWGSOP reviewed 
several tools to evaluate body composition and found that dual-energy X-ray absorptiometry 
and BIA are the most suitable for clinical use [15]. However, no arguments exist to support the 
believe that the relationships described occur exclusively in the population from which our 
simple is taken, given that the results were observed to converge with data described in other 
national and international studies.  
5. Conclusions 
In synthesis, the results from this research indicates that one in every five women who have 
survived breast cancer has sarcopenia (i.e atrophy and muscle performance impairments). 
Additionally, our analysis seems to emphasize the importance of obesity prevention in women 
survivors of breast cancer, suggesting that high levels of handgrip strength may not relate 
closely to greater muscle mass. Even though it is true that these changes are due to a multifactor 
process, our findings seem suggest that interventions aimed at optimizing these aspects could 
be of vital importance to maintain a healthy body composition in this type of population. 
Observational studies with larger sample sizes and in other populations and age groups are 
required, especially longitudinal and prospective studies, to verify the results obtained in this 
work. 
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